AC
ACRS.US Aclaris Therapeutics Inc
- Market cap
- USD 620M
- P/E
- -
- P/B
- 3.81x
- ROE
- -47.8%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is ACRS.US undervalued?
Graham numberThe Graham number of Aclaris Therapeutics Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Aclaris Therapeutics Inc fundamental analysis
No fundamental analysis for Aclaris Therapeutics Inc yet.
Aclaris Therapeutics Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Aclaris Therapeutics Inc
Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering and developing novel molecule product candidates for immuno-inflammatory diseases in the United States. The company product pipeline includes Bosakitug (ATI-045), an anti-thymic stromal lymphopoietin monoclonal antibody in Phase 2 trial to treat moderate to severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and moderate to severe chronic obstructive pul…
Full company profileAclaris Therapeutics Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Aclaris Therapeutics Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 0.00 | 1.68M | 10.1M | 4.23M | 6.48M | 6.76M | 29.8M | 31.2M | 18.7M | 7.83M | 6.81M |
| Gross Profit | -120K | 476K | 3.24M | 172K | 1.35M | 2.05M | 17.8M | 13.2M | 15.9M | 5.74M | 5.72M |
| Operating Income | -48.6M | -72.4M | -135M | -111M | -50.9M | -89.7M | -89.9M | -97.4M | -142M | -76.4M | -90.4M |
| EBITDA | -48.4M | -72.0M | -134M | -90.2M | -49.6M | -64.5M | -84.4M | -115M | -51.7M | -64.5M | -79.4M |
| Net Income | -48.1M | -68.5M | -133M | -161M | -51.2M | -90.9M | -86.9M | -88.5M | -132M | -64.9M | -79.8M |
| EPS | -2.25 | -2.44 | -4.03 | -3.90 | -1.20 | -1.60 | -1.33 | -1.27 | -1.71 | -0.53 | -0.53 |
| Balance Sheet | |||||||||||
| Total Assets | 176M | 244M | 276M | 98.3M | 70.8M | 251M | 255M | 197M | 220M | 160M | 216M |
| Total Liabilities | 6.60M | 18.2M | 60.4M | 28.4M | 33.1M | 53.9M | 57.0M | 40.2M | 64.8M | 57.4M | 49.4M |
| Shareholders' Equity | 169M | 225M | 215M | 69.9M | 37.7M | 197M | 198M | 157M | 156M | 103M | 167M |
| Cash & Short-term Investments | 174M | 209M | 168M | 75.0M | 54.1M | 191M | 218M | 119M | 114M | 90.8M | 114M |
| Total Debt | - | 142K | 30.5M | 658K | 11.3M | 693K | 684K | 426K | 2.60M | 2.12M | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | -34.6M | -54.7M | -101M | -96.4M | -38.6M | -52.1M | -67.6M | -78.3M | -20.1M | -47.1M | -82.8M |
| Capital Expenditure | 232K | 1.24M | 1.36M | 1.61M | 453K | 308K | 605K | 1.31M | 121K | 111K | 112K |
| Free Cash Flow | -34.8M | -55.9M | -102M | -98.1M | -39.1M | -52.4M | -68.2M | -79.6M | -20.2M | -47.2M | -82.9M |
| Ratios | |||||||||||
| ROE | -28.4% | -30.4% | -61.7% | -230.8% | -135.9% | -46.0% | -44.0% | -56.3% | -84.9% | -63.0% | -47.8% |
| ROA | -27.3% | -28.1% | -48.2% | -164.1% | -72.3% | -36.2% | -34.1% | -44.8% | -59.9% | -40.5% | -36.9% |
| Net Profit Margin | - | -4,071.5% | -1,315.4% | -3,817.2% | -789.2% | -1,344.0% | -292.1% | -283.1% | -705.5% | -829.6% | -1,171.9% |
| Debt to Equity | - | 0.00x | 0.14x | 0.01x | 0.30x | 0.00x | 0.00x | 0.00x | 0.02x | 0.02x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Aclaris Therapeutics Inc dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | USD 3.12M | 0.06 | - |
| 2020 | USD 7.74M | 0.18 | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Aclaris Therapeutics Inc
- Insiders 2.03%
- Institutions 82.54%
- Public & others 15.43%
- Shares outstanding 159M
- Free float 114M
Top funds holding ACRS.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 4.24M | 2.68% | 0.00% | Sep 2026 |
| iShares Russell 2000 ETF | 3.01M | 1.89% | 0.00% | Oct 2026 |
| Fidelity Advisor Biotechnology I | 1.93M | 1.22% | +8.43% | Sep 2026 |
| Fidelity Small Cap Index | 1.30M | 0.82% | 0.00% | Aug 2026 |
| State Street® SPDR® S&P® PhrmctlsETF | 1.02M | 0.64% | +2.88% | Oct 2026 |
| iShares Russell 2000 Growth ETF | 972K | 0.61% | -0.38% | Oct 2026 |
| iShares Biotechnology ETF | 878K | 0.55% | -0.19% | Oct 2026 |
| Fidelity Enhanced Small Cap Core ETF | 867K | 0.55% | +0.27% | Oct 2026 |
| Fidelity Select Biotechnology | 775K | 0.49% | 0.00% | Aug 2026 |
| Schwab US Small-Cap ETF™ | 721K | 0.45% | +0.24% | Oct 2026 |
| Putnam Global Health Care A | 708K | 0.45% | 0.00% | Sep 2026 |
| Vanguard Russell 2000 ETF | 688K | 0.43% | +0.96% | Sep 2026 |
| Fidelity Extended Market Index | 611K | 0.39% | -0.41% | Sep 2026 |
| Biotech Growth Ord | 606K | 0.38% | +43.72% | Jul 2026 |
| Invesco Dorsey Wright SmallCap Momt ETF | 563K | 0.35% | -0.54% | Oct 2026 |
| Fidelity® SAI Small-Mid Cap Momt Idx | 372K | 0.23% | -3.93% | Sep 2026 |
| iShares Micro-Cap ETF | 359K | 0.23% | 0.00% | Oct 2026 |
| Vanguard US Momentum Factor ETF | 321K | 0.20% | -1.21% | Sep 2026 |
| Schwab Small Cap Index | 288K | 0.18% | 0.00% | Sep 2026 |
| Strategic Advisers Fidelity US TtlStk | 287K | 0.18% | 0.00% | Sep 2026 |
Top institutions holding ACRS.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| RA Capital Management, LLC | 12.7M | 8.44% | +86.99% | Jun 2026 |
| BML Capital Management LLC | 12.0M | 7.94% | -15.96% | Jun 2026 |
| BlackRock Inc | 10.0M | 6.65% | +35.51% | Jun 2026 |
| Deep Track Capital, LP | 9.35M | 6.20% | 0.00% | Jun 2026 |
| Vivo Capital, LLC | 6.69M | 4.44% | +0.42% | Jun 2026 |
| Vanguard Capital Management, LLC | 5.82M | 3.86% | +12.59% | Jun 2026 |
| Frazier Life Sciences Management, L.P. | 4.93M | 3.27% | 0.00% | Jun 2026 |
| Rock Springs Capital Management LP | 4.33M | 2.87% | -3.18% | Jun 2026 |
| Adage Capital Partners Gp LLC | 4.07M | 2.70% | +5.17% | Jun 2026 |
| Decheng Capital LLC | 4.04M | 2.68% | 0.00% | Jun 2026 |
| Kalehua Capital Management LLC | 3.66M | 2.43% | +15.61% | Jun 2026 |
| State Street Corp | 3.26M | 2.16% | +62.06% | Jun 2026 |
| Geode Capital Management, LLC | 3.19M | 2.12% | +31.62% | Jun 2026 |
| BRAIDWELL LP | 2.14M | 1.42% | +26.09% | Jun 2026 |
| Balyasny Asset Management LLC | 2.02M | 1.34% | -39.80% | Jun 2026 |
| SILVERARC CAPITAL MANAGEMENT, LLC | 1.95M | 1.29% | 0.00% | Jun 2026 |
| Citadel Advisors Llc | 1.76M | 1.17% | -21.66% | Jun 2026 |
| Jones Hill Capital LP | 1.76M | 1.17% | 0.00% | Jun 2026 |
| Acadian Asset Management LLC | 1.64M | 1.09% | +6.60% | Jun 2026 |
| Palo Alto Investors, LLC | 1.61M | 1.07% | 0.00% | Jun 2026 |
Aclaris Therapeutics Inc company profile
- Company name
- Aclaris Therapeutics Inc
- Ticker
- ACRS.US
- Exchange
- USA Stocks
- Listed since
- Oct 7, 2015
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 69
- Fiscal year end
- December
- Address
- 701 Lee Road, Wayne, PA, United States, 19087
- Phone
- 484 324 7933
- Website
- aclaristx.com
About Aclaris Therapeutics Inc
Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering and developing novel molecule product candidates for immuno-inflammatory diseases in the United States. The company product pipeline includes Bosakitug (ATI-045), an anti-thymic stromal lymphopoietin monoclonal antibody in Phase 2 trial to treat moderate to severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and moderate to severe chronic obstructive pulmonary disease; ATI-2138, an potent and selective novel investigational dual inhibitor of ITK and JAK3 in Phase 2a trial for the treatment for T cell-mediated autoimmune diseases; ATI-052, a humanized anti-TSLP and anti-IL4R bispecific antibody in Phase 1b to treat various atopic, immunologic, and respiratory diseases; ATI-9494, an oral, covalent, investigational dual inhibitor of ITK and Resting Lymphocyte Kinase (TXK), and other covalent JAK-sparing ITK inhibitors to treat modulate T cell biology across various diseases; and Lepzacitinib, a soft JAK 1/3 inhibitor for the treatment of atopic dermatitis and other dermatologic conditions. Aclaris Therapeutics, Inc. was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
Aclaris Therapeutics Inc management
10- Dr. Neal S. Walker D.O., M.D.Co-Founder, CEO & Chairman · born 1970
- Dr. Hugh M. Davis Ph.D.President, COO & Director · born 1960
- Mr. Kevin BalthaserChief Financial Officer · born 1987
- Mr. James LoeropChief Business Officer · born 1965
- Dr. Roland Kolbeck Ph.D.Chief Scientific Officer · born 1964
- Mr. William C. RobertsSenior Vice President of Corporate Communications & Investor Relations · born 1969
- Mr. Matthew Rothman J.D.General Counsel & Corporate Secretary
- Mr. Steve TuckerExecutive Vice President of Project Leadership
- Dr. Jesse W. Hall M.D.Chief Medical Officer · born 1974
- Ms. Nina Samra M.S.Senior Vice President of Clinical Operations